drugset / Trial / NCT00469378
Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a study to count the number of white blood cells in the cerebrospinal fluid and blood at the beginning and end of treatment with firategrast and at 4 and 12 weeks after stopping firategrast. Cerebrospinal fluid flows through and protects the brain and spinal cord. It is important to understand what happens to the number of white blood cells because they are important in preventing infections.
Timeline
- Start
- 2007-07
- Primary completion
- 2009-05
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firategrast | Small molecule | 900 mg | — |
| Subject | Firategrast | Small molecule | 1200 mg | — |